A 54 week, extension to the double-blind, multicenter, multifactorial, placeco-controlled, study to evaluate the efficacy and safety of valsartan (160 mg and 320 mg) and amlodipine (10 mg) combined and alone in hypertensive patients.

Trial Profile

A 54 week, extension to the double-blind, multicenter, multifactorial, placeco-controlled, study to evaluate the efficacy and safety of valsartan (160 mg and 320 mg) and amlodipine (10 mg) combined and alone in hypertensive patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2011

At a glance

  • Drugs Amlodipine; Valsartan
  • Indications Hypertension
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top